Table 4.

Current ongoing clinical trials for VISTA-specific monoclonal antibodies or antagonist agents.

Name of the compound	Mechanism of action	Study phase	Trial ID	Targeted population	Status
CI-8993	Human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand	Phase I	ClinicalTrials.gov NCT04475523	Patients with relapsed/refractory solid tumors	Recruiting
JNJ-61610588	Human IgG1 kappa anti-VISTA monoclonal antibody	Phase I	ClinicalTrials.gov NCT02671955	Participants with advanced cancer	Terminated
CA-170	Small molecule (PD-L1/PD-L2), and (VISTA) antagonist	Phase I	ClinicalTrials.gov NCT02812875	Adult patients with advanced solid tumors or lymphomas who have progressed or are nonresponsive to available therapies and for which no standard therapy exists	Completed

PD-L1, programmed cell death-ligand 1; VISTA, V-domain Ig suppressor of T-cell activation.